Evidence map›Paper›PMID 37705795›Full record

ArticleNanoscale advances2023

A bacterial cellulose-based LiSrVO

Mohammad Mahdavi, Hamid Emadi, Seyed Reza Nabavi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohammad MahdaviDepartment of Applied Chemistry, Faculty of Chemistry, University of Mazandaran Babolsar Iran h.emadi@umz.ac.ir m.mahdavi10@umail.umz.ac.ir srnabavi@umz.ac.ir.ORCID https://orcid.org/0009-0008-9599-1957
Hamid EmadiDepartment of Applied Chemistry, Faculty of Chemistry, University of Mazandaran Babolsar Iran h.emadi@umz.ac.ir m.mahdavi10@umail.umz.ac.ir srnabavi@umz.ac.ir.ORCID https://orcid.org/0000-0002-2764-7264
Seyed Reza NabaviDepartment of Applied Chemistry, Faculty of Chemistry, University of Mazandaran Babolsar Iran h.emadi@umz.ac.ir m.mahdavi10@umail.umz.ac.ir srnabavi@umz.ac.ir.ORCID https://orcid.org/0000-0002-2605-6710

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among the catecholamines, dopamine (DA) is essential in regulating multiple aspects of the central nervous system. The level of dopamine in the brain correlates with neurological diseases such as Parkinson's disease (PD). However, dopamine is unable to cross the blood-brain barrier (BBB). Therefore, levodopa (LD) is used to restore normal dopamine levels in the brain by crossing the BBB. Thus, the control of LD and DA levels is critical for PD diagnosis. For this purpose, LiSr

Identifiers

PMID37705795
PMCPMC10496915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.